RevolKa Reimagines Antibody Engineering with "RevoAb®"

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa's advanced AI Protein Engineering Engine

SENDAI, Japan- Apr 1st, 2026. RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called ***ai*Protein®**, is pleased to announce the official global launch of **RevoAb®**, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially **antibody yields**.

■ RevoAb®: The Next-Gen AI Antibody Design

Since December 2023, RevolKa has provided an antibody optimization services utilizing *ai*Protein®. The newly launched **RevoAb®** is a quick intuitive online antibody sequence optimization service that integrates RevolKa's core technology—the **"Refined Naturalness Framework Engineering"**. **RevoAb®** is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially **protein expression levels**, without trade-off of affinity. This allows researchers worldwide to experience RevolKa's high-performance antibody design.

■ Key Advantages of RevoAb®

- **Speed:** Multiple optimized sequence candidates for improved physicochemical properties **in a day, not weeks**
- **Satisfaction**: Proven records, **92% success rate**, by Japanese pharmaceutical and academic customers (including internal data), particularly with significant improvements in protein expression levels during the pre-launch period beginning July 2025
- **Low cost**: Starting at **$700 USD** per antibody for exploring physicochemical property improvements, **"Start with RevoAb®, Scale with *ai*Protein®** , high-value, fully customized AI antibody engineering"

- **ZERO Complex AI Configurations**: No specialized AI and bioinformatics expertise and expert-level AI parameter tuning, making advanced AI design accessible to every researcher
- **High Modality and Species Compatibility**: Wide-Range of antibody modalities, from monoclonal IgG to the next-gen antibodies, such as variable fragment formats (Fv, VHH) across diverse species including human, mouse, rat, rabbit, chicken, llama, etc.

For details, visit the RevoAb® Service Site: https://revoab.revolka.com/en/

■ Proven Success in Japan

Throughout the pilot phase, RevoAb® has successfully contributed to solving critical challenges for Japanese pharmaceutical companies, biotech ventures, and universities. The service has earned a strong reputation for its ability, for example, to overcome production issues. An example is shown below. One of the three RevoAb® generated sequences of a difficult-to-express single chain Fv showed 7x higher expression levels in E.coli without serious change in affinity.

■ Background: Minimizing Lead Time and R&D Costs

Antibodies are essential across various industries, from therapeutics to diagnostics. However, optimizing their characteristics, such as stability, affinity, and productivity, remains a significant technical hurdle requiring substantial time and investment.

RevolKa helps to break these barriers by providing researchers worldwide with direct, simple access to the power of ***ai*Protein®**. By streamlining the design process, **RevoAb®** empowers scientists to focus on breakthrough discoveries.

■ Contact Information

For inquiries regarding the service or potential collaborations, please contact us via the form on our service site:
https://revoab.revolka.com/en/

■ About RevolKa Ltd.

RevolKa is a biotechnology company specialized in protein engineering using its proprietary AI platform, *ai*Protein®. The company is committed to accelerating the development of novel biologics and industrial enzymes to improve human health and sustainability.